What Is the Yellow Card Scheme? How the UK Tracks Medication Side Effects
Last updated: 8 August 2026
TL;DR: The Yellow Card scheme is the UK's national system, run by the MHRA, for reporting suspected problems with medicines, vaccines and devices. Anyone can report. A Yellow Card report records a suspicion, not proof that a medicine caused harm, which is why report totals must be read alongside prescription volume.
When headlines cite the number of deaths or reactions "linked" to weight loss injections, the figures almost always come from the Yellow Card scheme. Understanding what the scheme is, and what its numbers do and do not mean, is the difference between an accurate read of medication safety and a misleading one.
What Is the Yellow Card Scheme and Who Runs It?
The Yellow Card scheme is the UK's spontaneous reporting system for suspected adverse reactions to medicines and safety issues with medical products. It is run by the Medicines and Healthcare products Regulatory Agency (MHRA), the body responsible for regulating medicines in the UK. It has operated since 1964 and now covers medicines, vaccines, medical devices, blood products and e-cigarettes.
The scheme exists to detect safety signals early. By gathering suspicions from across the country into one dataset, the MHRA can spot patterns that no single clinician would see, then investigate and act. It is an early-warning system, not a register of proven harms.
What Does a Yellow Card Report Actually Mean?
A report means someone suspected a link between a medicine and a symptom or outcome and logged it. It does not mean the medicine caused the event. The MHRA states this directly: a report "did not necessarily mean that the death or the reaction was caused by the medicine, only that the reporter had a suspicion."
This matters because spontaneous reports cannot, on their own, establish cause. A patient taking a widely used medicine may experience an unrelated illness; that event can still be reported in good faith. The MHRA weighs reports against prescribing data, clinical trials and scientific literature before drawing conclusions, which is why a single total is never the full picture.
How Do Patients Report a Side Effect Themselves?
Patients do not need a clinician to report. Anyone can submit a Yellow Card directly to the MHRA, and patient reports are a valued part of the dataset because they capture experiences that may not reach a prescriber.
- Go to the official portal at yellowcard.mhra.gov.uk, or use the Yellow Card app.
- Search for the medicine, vaccine or device involved.
- Describe the suspected reaction, when it started, and relevant details such as dose and other medicines.
- Submit; no login is required, and reports can be made on behalf of someone else.
Reporting is quick and contributes to the same monitoring that produces the figures in the news. For GLP-1 medicines, patient reports have helped build the safety picture the MHRA reviews continuously.
Why Do Report Numbers Rise When Prescribing Rises?
Report totals track how many people take a medicine and how aware they are of potential effects, not just how risky the medicine is. As GLP-1 prescribing surged across the UK, report counts rose with it, which is expected and does not by itself indicate a new danger.
According to the BMJ (Iacobucci, 2025), UK data showed 82 deaths related to suspected GLP-1 reactions in early 2025; totals climbed through 2026 as usage expanded. The MHRA's own framing is that "reporting volumes can be influenced by increased use, greater awareness of a potential adverse reaction and other factors." A rising number is a prompt to investigate, not a conclusion.
| What changed | Effect on report count | Effect on actual per-patient risk |
|---|---|---|
| More prescriptions issued | Rises | No necessary change |
| More media coverage of a risk | Rises | No necessary change |
| A genuine new safety signal | Rises | May rise; triggers MHRA review |
How Should You Interpret Media Headlines About Drug Reports?
Read a "linked to X deaths" headline as a count of suspicions awaiting context, not a verdict. The two questions that resolve most confusion are: how many people take the medicine, and has the regulator identified a confirmed signal? Without the denominator, a large raw number is uninformative.
The MHRA acts when evidence warrants it. In January 2026 it updated GLP-1 product information to reflect a small risk of severe acute pancreatitis, and through the Yellow Card Biobank with Genomics England it is investigating whether genes influence that risk. That is the scheme functioning: suspicion collected, signal reviewed, guidance updated. On current evidence, the MHRA holds that the benefits of GLP-1 medicines outweigh the risks when used as authorised.
Related Guides
- Are Weight Loss Injections Safe? What the UK Data Actually Shows
- GLP-1 Warning Signs: When Weight Loss Medication Side Effects Need Medical Attention
- How to Manage Common GLP-1 Side Effects: A Practical Patient Guide
- How Bolt Prescribes: Our Clinical Process
Key Takeaways
- The Yellow Card scheme is the MHRA's national system for reporting suspected medicine safety issues.
- Anyone can report, and a report records suspicion, not proven causation.
- Rising GLP-1 report totals largely reflect rising prescribing and awareness, not a proven rise in risk.
- The MHRA reviews reports against prescribing data, trials and literature before acting.
- Read "linked to X deaths" headlines as suspicions needing the prescription-volume denominator.
Frequently Asked Questions
What is the Yellow Card scheme?
It is the UK's national system, run by the MHRA, for collecting suspected side effects and safety problems with medicines, vaccines and medical devices. It has run since 1964 and works as an early-warning system to detect safety signals for investigation.
Does a Yellow Card report mean a medicine caused harm?
No. A report means someone suspected a link and logged it. The MHRA states a report does not necessarily mean the medicine caused the event. Reports are reviewed alongside prescribing data and other evidence before any conclusion is drawn.
Can patients submit a Yellow Card themselves?
Yes. Patients, carers and the public can report directly at yellowcard.mhra.gov.uk or via the Yellow Card app, without a clinician and without a login. Patient reports are a valued part of the safety dataset the MHRA monitors.
Why are there so many GLP-1 reports?
Because prescribing volume and public awareness have both risen sharply. Higher report totals largely reflect more people using the medicines and more attention on potential effects, not a proven increase in per-patient risk.
Published by Bolt Pharmacy, a GPhC-registered UK pharmacy. Sources: MHRA Yellow Card scheme (yellowcard.mhra.gov.uk); Iacobucci, BMJ (2025;388:r390); MHRA and Genomics England Yellow Card Biobank (2025); MHRA GLP-1 guidance update (January 2026). Educational only; not a substitute for professional medical advice. Reflects published information as of August 2026.
